M Dowsett

Summary

Affiliation: National University of Singapore
Country: Singapore

Publications

  1. ncbi Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
    J Chang
    Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    J Clin Oncol 17:3058-63. 1999
  2. ncbi Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
    J Chang
    Department of Biochemistry, Medicine and Computing, The Royal Marden Hospital, Sutton, Surrey, United Kingdom
    Cancer 89:2145-52. 2000
  3. ncbi Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
    A Makris
    Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 48:11-20. 1998
  4. ncbi Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
    L Assersohn
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 82:113-23. 2003
  5. ncbi A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
    T J Powles
    Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 60:126-31. 1989

Collaborators

Detail Information

Publications5

  1. ncbi Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
    J Chang
    Departments of Medicine and Computing, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    J Clin Oncol 17:3058-63. 1999
    ..To determine whether pretreatment clinical features and molecular markers, together with changes in these factors, can predict treatment response and survival in patients with primary operable breast cancer who receive neoadjuvant therapy...
  2. ncbi Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
    J Chang
    Department of Biochemistry, Medicine and Computing, The Royal Marden Hospital, Sutton, Surrey, United Kingdom
    Cancer 89:2145-52. 2000
    ..The objective of this clinical study was to examine in vivo changes in apoptotic index (AI), Bcl-2 expression, proliferation (Ki-67 and S-phase fraction [SPF]), and ploidy as potential indicators of chemoresponsiveness...
  3. ncbi Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
    A Makris
    Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 48:11-20. 1998
    ..To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer...
  4. ncbi Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
    L Assersohn
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 82:113-23. 2003
    ..CONCLUSION: Ki67 is unlikely to be useful as a predictive marker in individual patients. Further molecular markers that predict lack of response continue to be required...
  5. ncbi A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
    T J Powles
    Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 60:126-31. 1989
    ..At this stage no untoward long-term risks have been identified, and it is therefore proposed that a large multicentre trial should be started...